Literature DB >> 4004859

Maytansine inhibits nucleotide binding at the exchangeable site of tubulin.

A B Huang, C M Lin, E Hamel.   

Abstract

The antineoplastic drug maytansine inhibits the binding of exogenously added radiolabeled GDP and GTP to tubulin (50% inhibition at 9-10 microM drug at 0 degrees). Vinblastine was 1/10-th as inhibitory. Neither maytansine nor vinblastine displaced GDP from tubulin, and both drugs virtually eliminated dissociation of radiolabeled GDP from the exchangeable site. Maytansine also inhibits binding of nucleotides to a vacant exchangeable site. Maytansine thus prevents nucleotide exit and entry at the exchangeable site because of a direct physical obstruction or a conformational change in the tubulin molecule.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4004859     DOI: 10.1016/0006-291x(85)91073-3

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

1.  Synthesis of two fluorescent GTPγS molecules and their biological relevance.

Authors:  Denise J Trans; Ruoli Bai; J Bennet Addison; Ruiwu Liu; Ernest Hamel; Matthew A Coleman; Paul T Henderson
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2017-03-10       Impact factor: 1.381

2.  Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability.

Authors:  Emin Oroudjev; Manu Lopus; Leslie Wilson; Charlene Audette; Carmela Provenzano; Hans Erickson; Yelena Kovtun; Ravi Chari; Mary Ann Jordan
Journal:  Mol Cancer Ther       Date:  2010-10       Impact factor: 6.261

3.  Two engineered site-specific antibody-drug conjugates, HLmD4 and HLvM4, have potent therapeutic activity in two DLL4-positive tumour xenograft models.

Authors:  Shijing Wang; Hui Wen; Wenyi Fei; Yuhong Zhao; Yuqi Feng; Lu Kuang; Min Wang; Min Wu
Journal:  Am J Cancer Res       Date:  2020-08-01       Impact factor: 5.942

Review 4.  A Review on Mechanistic Insight of Plant Derived Anticancer Bioactive Phytocompounds and Their Structure Activity Relationship.

Authors:  Kishor Mazumder; Asma Aktar; Priyanka Roy; Biswajit Biswas; Md Emran Hossain; Kishore Kumar Sarkar; Sitesh Chandra Bachar; Firoj Ahmed; A S M Monjur-Al-Hossain; Koichi Fukase
Journal:  Molecules       Date:  2022-05-09       Impact factor: 4.927

5.  Characterisation of antimitotic products from marine organisms that disorganise the microtubule network: ecteinascidin 743, isohomohalichondrin-B and LL-15.

Authors:  M García-Rocha; M D García-Gravalos; J Avila
Journal:  Br J Cancer       Date:  1996-04       Impact factor: 7.640

6.  Ansamitocin P3 depolymerizes microtubules and induces apoptosis by binding to tubulin at the vinblastine site.

Authors:  Jubina B Venghateri; Tilak Kumar Gupta; Paul J Verma; Ambarish Kunwar; Dulal Panda
Journal:  PLoS One       Date:  2013-10-04       Impact factor: 3.240

7.  Characterization of the interaction of TZT-1027, a potent antitumor agent, with tubulin.

Authors:  T Natsume; J Watanabe; S Tamaoki; N Fujio; K Miyasaka; M Kobayashi
Journal:  Jpn J Cancer Res       Date:  2000-07

8.  Increased yield of AP-3 by inactivation of asm25 in Actinosynnema pretiosum ssp. auranticum ATCC 31565.

Authors:  Hong Cheng; Guoqing Xiong; Yi Li; Jiaqi Zhu; Xianghua Xiong; Qingyang Wang; Liancheng Zhang; Haolong Dong; Chen Zhu; Gang Liu; Huipeng Chen
Journal:  PLoS One       Date:  2022-03-22       Impact factor: 3.240

9.  Esophageal cancer cells resistant to T-DM1 display alterations in cell adhesion and the prostaglandin pathway.

Authors:  Juliette Sauveur; Eva-Laure Matera; Kamel Chettab; Philippe Valet; Jerome Guitton; Ariel Savina; Charles Dumontet
Journal:  Oncotarget       Date:  2018-04-20

Review 10.  Stepping forward in antibody-drug conjugate development.

Authors:  Yiming Jin; Megan A Schladetsch; Xueting Huang; Marcy J Balunas; Andrew J Wiemer
Journal:  Pharmacol Ther       Date:  2021-06-24       Impact factor: 12.310

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.